MLMartin Dominik Lohri

Martin Dominik Lohri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Dominik Lohri has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The PROTECT trial: Effect of titrated versus conventional induction of general anaesthesia using a target-controlled infusion system on haemodynamics in patients undergoing non-cardiac surgery – protocol for a multicentre, expertise-based randomised controlled trial

    by Simon Funk, Martin Dominik Lohri, Andrea Kopp Lugli, Christian Schindler, Andrea Wiencierz, Kristian Mnich, Martin Schläpfer, Alexander Peter Gaberdiel, Milo Alan Puhan, Luzius A Steiner, et al.

    Introduction: Hypotension is a frequent complication after induction of general anaesthesia leading to end-organ injury, for which elderly and multimorbid patients are particularly susceptible. The extent of hypotension depends, among other factors, on the dose and rate of propofol administration. Target-controlled infusion systems are widely used to administer short-acting anaesthetics such as propofol and remifentanil. Commonly, induction is started with a fixed effect-site concentration. Titration, an alternative method of induction using an incremental augmentation of propofol, leads to a reduced induction dose and rate of propofol. We hypothesise that the titration method improves haemodynamic stability compared with conventional induction. Methods and analysis: This multicentre, expertise-based randomised controlled trial takes place at four Swiss hospitals. Patients ≥55 years of age undergoing non-cardiac surgery under general anaesthesia using propofol target-controlled infusion are randomised to either a conventional or a titrated anaesthesia induction method. Patients, statisticians and, if resources allow, outcome assessors will be blinded. The primary endpoint is the mean arterial pressure under the individual baseline mean arterial pressure (area under threshold) during the first 30 min after start of induction. Secondary endpoints include the maximum deviation from baseline mean arterial pressure, haemodynamic rescue methods, propofol consumption and neurocognitive recovery after regaining consciousness. A total of 320 patients are required to have an 80% chance of observing superiority of titration for the area under the threshold as significant at the 5% level, assuming a true difference of 100 mm Hg*min. The area under threshold and the maximum deviation will be compared between arms using mixed linear regression models. Ethics and dissemination: Ethical approval has been obtained from all responsible ethics committees (BASEC2025-01007). The results will be presented at international meetings and published in peer-reviewed journals and may contribute to a change in clinical practice for anaesthesia induction using target-controlled infusion systems with propofol. Trial registration number: clinicaltrials.gov ( NCT06980688 ) and www.humanforschung-schweiz.ch (HumRes67022).

  • The effect of raw EEG implementation for assessing depth of anaesthesia on patient quality of recovery

    by Martin Dominik Lohri, Anita Luethy, Wilhelmus Johannes Maria Schellekens, Bettina Ursina Gruber, Lisa Hert, Lien Jakus, Julien Maillard, Christian Schindler, Luzius A. Steiner, Christoph Simon Burkhart, et al.

    BACKGROUND: Processed electroencephalography is widely used to assess depth of anaesthesia and to titrate anaesthetics, thereby increasing the quality of recovery. However, the processed electroencephalogram is influenced by technical, patient, and anaesthetic factors. Adding information from the frontal real-time raw electroencephalogram may help to overcome these limitations. OBJECTIVE: To assess the effect of a raw electroencephalogram tutorial and its intra-operative implementation versus standard care on postoperative quality of recovery and propofol consumption. DESIGN: Multicentre double-blind randomised controlled trial. SETTING: The trial was conducted at four tertiary centres in Switzerland. PATIENTS AND ANAESTHESIA PRACTITIONERS: We screened 534 adult patients undergoing in-hospital laparoscopies and 346 anaesthesia practitioners with at least 2 years of anaesthesia experience. We matched and randomised 232 pairs and analysed 209. The patients were 78% female. INTERVENTION: The anaesthesia practitioners assigned to the patients were randomised to a validated tutorial for assessing depth of anaesthesia with the raw electroencephalogram or to a no tutorial group. Monitoring included raw and processed electroencephalogram for patients allocated to the tutorial and only processed electroencephalogram for the no tutorial group. MAIN OUTCOME MEASURES: The primary outcome was quality of recovery on the first postoperative day measured with the QoR-15 score. The first secondary outcome was propofol consumption. Groups were compared with a two-sample t -test. RESULTS: We found no statistically significant difference between the tutorial and the no tutorial group with mean differences of −3.2 [95% confidence interval (CI), −8.8 to 2.5, P = 0.273] for QoR-15 score and 0.36 mg kg −1 h −1 (95% CI, −0.01 to 0.73, P = 0.055) for propofol consumption. CONCLUSION: A short tutorial on the raw electroencephalogram and its addition intra-operatively was not able to improve quality of recovery or reduce propofol consumption in middle-aged, largely female patients. A more in-depth tutorial applied to more vulnerable patients might have shown different results.


  • Open Access

    Prevalence, clinical impact and associated patient-centred outcomes of advance directives in Swiss intensive care units: Results from the retrospective ADVISE Study

    by Sira Maria Baumann, Dominik Vock, Paulina S. C. Kliem, Simon A. Amacher, Yasmin Erne, Pascale Grzonka, Sebastian Berger, Martin Lohri, Sabina Hunziker, Caroline E. Gebhard, et al.

    STUDY AIMS: Data on the usefulness of advance directives for end-of-life decision-making in intensive care units (ICUs) are scarce. The primary aim of the present study was to investigate the prevalence of advance directives in patients of two Swiss ICUs. To contextualise how advance directives are created, interpreted and translated into clinical practice and which patient profiles influence whether and how patients choose to formulate advance directives, secondary objectives included analysing their content, clinical translation, and associated patient characteristics and outcomes. METHODS: The retrospective cohort study was carried out at two tertiary Swiss ICUs.Data were collected from patients with advance directives treated in ICUs >48 hours from 2020 to 2022.The primary endpoint was the prevalence of advance directives and their content regarding life-prolonging measures, including cardiopulmonary resuscitation (CPR). RESULTS: Of the 5242 patients included, 313 (6.0%) had advance directives. While 290/313 (92.7%) consented to life-prolonging measures other than CPR, CPR was less frequently desired (217/313 [69.3%]). 14.0% (18/129) requested CPR despite declining life-prolonging measures. Fewer women consented to life-prolonging measures and/or CPR than men, whereas prior ICU stays were associated with higher consent rates. Of 104 treatment adaptations, 53 (51.0%) aligned with advance directives, while 33/104 adaptations (31.7%) were based on presumed poor prognosis and 4/104 (3.9%) on surrogate decisions. While patients declining life-prolonging measures experienced faster treatment changes, survival and functional outcomes did not differ based on consent status. CONCLUSIONS:The prevalence of patients with advance directives admitted to Swiss ICUs is low, and substantial obstacles must be overcome in clinical practice. Inconsistent or contradictory contenthighlightsa need for better preemptive communication and documentation of patients’ wishes. Respecting patient autonomy in choosing to forgo life-prolonging measures might not be associated with a lower likelihood of survival or functional outcomes. Trial registration: https://clinicaltrials.gov NCT04348318.